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Background: Herpes simplex virus type 2 (HSV-2) is sexually transmitted, leading to blisters and ulcers in the
genito-anal region. After primary infection the virus is present in a latent state in neurons in sensory ganglia.
Reactivation and production of new viral particles can cause asymptomatic viral shedding or new lesions.
Establishment of latency, maintenance and reactivation involve silencing of genes, continuous suppression of gene
activities and finally gene activation and synthesis of viral DNA. The purpose of the present work was to study the
genetic stability of the virus during these events.
Methods: HSV-2 was collected from 5 patients with true primary and recurrent infections, and the genes encoding
glycoproteins B,G,E and I were sequenced.
Results: No nucleotide substitution was observed in any patient, indicating genetic stability. However, since the
total number of nucleotides in these genes is only a small part of the total genome, we cannot rule out variation in
other regions.
Conclusions: Although infections of cell cultures and animal models are useful for studies of herpes simplex virus,
it is important to know how the virus behaves in the natural host. We observed that several glycoprotein gene
sequences are stable from primary to recurrent infection. However, the virus isolates from the different patients
were genetically different.
Keywords: Primary and recurrent infections of humans, Genetic stability of HSV-2Background
Herpes simplex viruses (HSV) are widely distributed
pathogens transmitted by close contact. Infection by
type 1 (HSV-1) starts in childhood and increases during
the following years so that more than 70% of the popula-
tion is seropositive at an age of 40 years [1]. HSV-1 af-
fects the orofacial region. Additionally it has become a
common cause of genital herpes infections, presently re-
sponsible for at least 50% of the cases in some regions
[2,3]. Encephalitis due to HSV-1 infection is a much
more rare, but devastating disease [4-7].* Correspondence: lars.haarr@k2.uib.no
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reproduction in any medium, provided the orHerpes simplex type 2 (HSV-2) is sexually transmitted,
leading to blisters and ulcers in the anogenital region
(for review, see ref. [8,9]). Prevalence of HSV-2 infections
shows geographical variation and marked differences from
one demographic group to another (reviewed in 1). It is
high among prostitutes [10,11], related to number of sexual
partners and to exposure to other sexually transmitted dis-
eases [12,13]. The average prevalence is 17% in USA [14]
and varies between 7% and 31% among European
adults [1]. There is a well-documented relationship be-
tween infections with HSV-2 and HIV-1 [12,15-17].
HSV-2 seropositivity increases the risk for HIV acquisi-
tion by a factor of 3 [15].
Together with varicella zoster virus (VZV) and pseudo-
rabies virus (PRV), HSV-1 and HSV-2 belong to thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Table 1 Patients included in the study
Patient no* Time between
primary and
recurrent infection
Treatment (valaciclovir)
Primary
infection
Recurrent
infection
1 4 months Yes No
2 2 weeks Yes Yes
3 3 weeks Yes No
4 3 months Yes Yes
5 6 weeks Yes Yes
*All patients were women between 19 and 35 years old.
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neurotropic, and like many other members of the herpesvir-
idae family cause latent infections. After primary infection
in the skin/mucosal membranes the virus enters axons of
innervating neurons, migrates retrograde and establishes
latent infections in neuronal cells in sensory ganglia.
Reactivation from latency is a commonly occurring event
during which the virus migrates anterograde in the axon,
leading to new infection in the periphery or to asymptom-
atic shedding of the virus. About 90% of the persons with
primary HSV-2 infection have recurrence during the first
year afterwards, and one fifth of them more than 10 times
during this period [18-20]. Reactivation of HSV-2 is most
frequent during the first years after primary infection. As
much as 75% of these events may be short asymptomatic
shedding lasting for approximately 12 hours [19].
The molecular processes involved during the various
steps of primary and recurrent infection have been stud-
ied extensively and reviewed in recent reports [21,22].
Neither virus particles nor viral antigens are produced
in the latent state, but latency-associated transcripts
(LATs) and several micro RNAs are formed [23-27].
Major regulatory steps in these events are silencing of
viral genes, continuous suppression of gene activities
and finally stimulation of such activities followed by
DNA synthesis. Several aspects of these processes have
been studied in cell culture and in animal models, but
with little focus on the genetic stability of the virus. The
purpose of the present work was to study this stability,
in the natural host, during these different series of
events. We isolated HSV-2 from true primary and recur-
rent infections and sequenced a set of selected genes.
The isolates were genetically different, but no sequence
differences were observed between the initial infection
and the reactivation.
Methods
Clinical HSV-2 isolates
HSV-2 isolates were collected from patients with genital
lesions attending a clinic for sexually transmitted dis-
eases in Bergen, Norway. Blood samples were analysed
for the presence of HSV-2 antibodies as described previ-
ously [28]. Briefly, an oligopeptide corresponding to
an antigen region in glycoprotein G of HSV-2 (gG-2)
was used in an enzyme-linked immunoabsorbent assay
(ELISA). Patients with primary infection were selected
on the basis that there was no information of previous
genital infection, and HSV-2-specific antibodies were
not detected when presenting with blisters and/or ulcers
for the first time. Five persons were included in the
study. Description of them is given in Table 1. The pa-
tients were examined again at the first reactivation of
genital herpes. Sterile Dacron swabs were used to collect
lesional specimens. The swabs were stored in liquidvirus transport medium. Virus from primary infection
was confirmed as HSV-2 by using nested PCR targeting
the type-specific promoter region of the gD-2 gene as
described by Cinque et al. [29] and slightly modified
[30]. The clinical isolates were analysed further at a low
passage number (less than 5).
Ethics and consent statement
The study was approved by the Regional Committee for
Medical and Health Research Ethics, Western-Norway,
University of Bergen. All patients were informed about
the various aspects of the project, including isolation of
virus from the samples, analysis of the viruses and publi-
cation of the results. The samples and results were
coded to by anonymous. Consent was obtained from all
patients.
DNA isolation, PCR amplification and sequencing
Virus DNA was isolated using the Qiagen DNeasy
Tissue Kit, as described by the manufacturer. The con-
centration varied from 25 to ≥ 1200 ng per μl. Three re-
gions of the HSV-2 genome were amplified prior to
sequencing. The UL27 gene (encoding glycoprotein B,
gB-2) was amplified as a 2942-bp fragment spanning the
region from 78 bp upstream of the start codon to
149 bp downstream of the termination codon (the posi-
tions refer to strain HG52). Several additional primers
were used for sequencing (Table 2). Amplification of the
US4 gene (encoding glycoprotein G, gG-2) and a frag-
ment containing both the US7 and US8 genes (encoding
glycoproteins gI and gE, gI-2 and gE-2, respectively) as
well as noncoding sequences between the two genes
were performed as described previously [31]. The frag-
ment including the US4 gene contained 57 bp upstream
and 39 bp downstream of the coding sequences. Similarly,
the latter fragment contained 57 bp upstream of the start
codon of the US7 gene and 47 bp downstream of the US8
gene. The primers used for amplification and sequencing of
the two latter fragments have been published [31,32].
PCR and gel electrophoresis of the amplified frag-
ments were performed as described previously [30].
Briefly, Tfl DNA polymerase (Epicentre, Madison, USA)
Table 2 Primers used for amplification and sequencing of
the gB gene
Nucleotide position Type Sequence
53254–53273 AS 5′-CCGTTAGCACATGTCTGCAT
53437–53456 S 5′-AGGTACTCTCCGCTCCACAA
53522–53541 AS 5′-TCTTTCTGGCCTTGTGTTCC
53710–53739 S 5′-CTACGTCCTGCAACTGCAAC
53801–53820 AS 5′-CGAAGGGGTTGGACATAAAG
54013–54032 S 5′-CTGCTGGACTACACGGAGGT
54108–54128 AS 5′-AGGTCGATGAAGGTGCTGAC
54299–54319 S 5′-GCTTTCGGTACGAAGACCAG
54371–54390 AS 5′-AGTTCTGCACGATCACGTTG
54510–54529 S 5′-ACCACGAGCTGACTCTCTGG
54730–54749 AS 5′-TACTCCCGCACGTACAGCTC
54943–54962 S 5′-ATCTCGACCACCTTCACCAC
55027–55046 AS 5′-CACTTGGTCATGGTGCAGAC
55232–55252 S 5′-TTGTGTACATGTCCCCGTTTT
55372–55391 AS 5′-TACTTGAGGTCGGTGGTGTG
55481–55500 S 5′-CAAGTACGTGCGGAACAACA
55643–55662 S 5′-CAAATTCAAGGCCACCATGT
55648–55667 AS 5′-GTGGCCTTGAATTTGTACGG
55914–55923 AS 5′-CTTTTTGGTTTTCCGCTTCC
55914–55923 S 5′-GGAAGCGGAAAACCAAAAAG
56176–56195 S 5′-CCATCCTCTACTCGGTCCTG
Nucleotide positions are given for the reference strain HG52, GenBank
accession number Z 86099.2. Boldface indicates primers used for amplification,
the rest were used for sequencing. S: sense. AS: antisense.
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used in a total volume of 50 μl containing 5 μl of diluted,
purified DNA extract. The incubation steps were 5 min
initial denaturation at 96°C, 30 cycles of denaturation at
95°C for 1 min, annealing of primers for 1 min at 57°C
for the US7-US8 fragment or at 60°C for the UL27 and
US4 fragments, elongation for 3 min at 68°C and a final
extension cycle at 68°C for 15 min.
Sets of overlapping primers as shown in Table 2 and
elsewhere [31,32] were used for sequencing. PCR prod-
ucts were treated with Exo-SAP (Affymetrix, Ca. USA)
and sequenced using the Big-Dye kit ver.3.1 (Life Tech.,
Ca. USA) Unincorporated dyes were removed using the
Big-Dye X-terminator purification kit (Life Tech., Ca.
USA) and the samples were analysed on an ABI 3730
sequencer (Life Tech., Ca. USA).
Sequence analysis
The sequences were analysed using the SeqScape soft-
ware (Life Tech., Ca. USA), using JN561323.1 in the
NCBI GenBank as a reference sequence. Sequences for
the reference strain and for the clinical isolates were con-
verted to FASTA (http://www.ebi.ac.uk/cgi-bin/readseq.cgi)and alignment performed using Clustal W2 (http://www.
ebi.ac.uk/Tools/msa/clustalw2/). Both programs are con-
nected to the EMBL-EBI database.
The genome of HSV-2 HG52 has two accession num-
bers in the GenBank, Z 86099.2 and JN 561323.2, re-
spectively. The latter was submitted more recently than
the former. Since previous published primers were also
used in the present study, and their nucleotides were
numbered with reference to Z 86099.2, the same refer-
ence was used for the new primers (Table 2). However,
when comparing the database sequences of various clin-
ical isolates with the reference strain, accession number
JN 561323.2 was used.
Results and discussion
To analyse for potential variation of the virus from primary
to recurrent infection, we focused on genes reported to
show polymorphism. They encode glycoprotein B (gB),
glycoprotein G (gG), glycoprotein I (gI) and glycoprotein E
(gE), respectively. The nucleotide diversity of these genes
can be studied by comparing the sequences of clinical iso-
lates of HSV-2 with the reference strain HSV-2 HG52. In
the NCBI GenBank each of these genes have been se-
quenced in a number of isolates, varying from 48 to 69.
The results of this comparison are shown in Table 3.
Substitutions affecting 2 isolates or more are specified.
A consistent feature was that whenever a substitution
was observed at a given position, it was identical in all
isolates affected, regardless of the number of isolates
subjected to change. This was the situation for all 4
genes. Except for deletion of 9 nucleotides in UL27 (gB),
and of three nucleotides at two different positions in
US4 (gG), the remaining changes were single nucleotide
substitutions. Reiteration of sequences may cause alter-
native alignment, as observed both for the gB and the
gG gene. Thus, alternative positions for substitutions
may be indicated by the computer. From positions 62 to
88 in the former gene the sequence CGG CGG CCC is
repeated three times. Similarly, CGG is repeated three
times from position 1277 to 1285 in the gG gene. Identi-
cal variations in the same position in two or more clin-
ical isolates indicate recombination. This was observed
at numerous sites in all genes and is consistent with the
fact that the isolates are from studies demonstrating
different clades of virus and recombination [31,33].
However, neither sequences nor positions for nucleotide
substitutions were given in these reports. In addition to
substitutions generated by recombination, a number of
single nucleotide substitutions affected only one clinical
isolate. Such changes could be generated by random mu-
tations or by recombination, but one cannot distinguish
between these possibilities.
Nucleotide diversity affecting one isolate only varied from
1.14% (UL27/gB) to 2.24% (US4/gG). Diversity affecting
Table 3 Sequence differences between HSV-2 HG52 and clinical isolates of HSV-2 in the database
Gene UL27/gB (2715nt) US4/gG (2100nt) US7/gI (1119nt) US8/gE (1638nt)
Total no. of isolates 69 64 49 48
Nucleotide diversity (%) affecting:
1 isolate 1.14 2.24 1.70 1.40
≥2 isolates 0.81 1.52 0.80 0.55
Position No. of
isolates
Substitutions,
comments
Position No. of
isolates
Substitutions,
comments
Position No. of
isolates
Substitutions,
comments
Position No. of
isolates
Substitutions,
comments
19 21 A ⇒ G 104 58 G ⇒ A 39 5 C ⇒ T 131 46 ins. GGC CGG
AGG
64-72 or
76-84*
66 del. GCC CCG GCG or
GCG GCC CCG
274 26 T ⇒ C 338 2 A ⇒ G 341 2 G ⇒ T
104 2 G ⇒ A 329 17 G ⇒ A 530 2 C ⇒ T 392 11 T ⇒ G
106 2 G ⇒ A 405 8 C ⇒ T 618 3 A ⇒ G 605 6 C ⇒ A
117 6 C ⇒ G 432 22 G ⇒ C 642 2 A ⇒ C 1146 8 A ⇒ G
146 48 G ⇒ A 611 10 C ⇒ T 643 13 C ⇒ T 1211 14 A ⇒ C
179 13 A ⇒ G 635 13 G ⇒ A 644 6 C ⇒ T 1245 2 C ⇒ T
210 8 C ⇒ T 872 3 A ⇒ G 716 45 T ⇒ G 1293 2 C ⇒ T
211 13 A ⇒ G 878-880 16 del. TCG 717 11 A ⇒ C 1621 44** C ⇒ T
850 2 C ⇒ T 891 4 G ⇒ A
989 16 G ⇒ A 930 50 C ⇒ T
1186 35 G ⇒ C 982 2 G ⇒ A
2247 47 A ⇒ C 993 2 G ⇒ T
Specification of substitutions
affecting ≥2 isolates
2533 29 G ⇒ C 1045 19 G ⇒ A
1048 64 A ⇒ G
1116 64 A⇒ G
1125 2 C ⇒ A
1268 37 T ⇒ C
1282-1285 or
1284-1286*
63 del.GCG or
GGC
1324 7 T ⇒ C
1419 2 A ⇒ G
1470 7 G ⇒ A
1510 3 A ⇒ G
H
aarr
et
al.BM
C
Infectious
D
iseases
2014,14:63
Page
4
of
8
http://w
w
w
.biom
edcentral.com
/1471-2334/14/63
Table 3 Sequence differences between HSV-2 HG52 and clinical isolates of HSV-2 in the database (Continued)
1722 2 G ⇒ T
1758 2 T ⇒ C
1761 7 G ⇒ C
1853 4 G ⇒ A
1994 2 T ⇒ G
*Alternative alignments. **Lacking sequences in the 3′- end of a few isolates. Nt nucleotides, Del Deletion, Ins insertion. Positions are numbered from the first nucleotide in the start codon.
H
aarr
et
al.BM
C
Infectious
D
iseases
2014,14:63
Page
5
of
8
http://w
w
w
.biom
edcentral.com
/1471-2334/14/63
Haarr et al. BMC Infectious Diseases 2014, 14:63 Page 6 of 8
http://www.biomedcentral.com/1471-2334/14/63two isolates or more was lower, but still highest for the US4
gene. These results indicate that the 4 selected genes might
be suitable candidates for detection of potential genetic
variation among viruses included in the present study.
All viral isolates were from females between 19 and 35
years old (Table 1). The time between collection of the
first virus sample (primary infection) and the second one
(recurrent infection) varied between 2 weeks and 4
months. All patients received treatment with valaciclovir
at the first episode and 3 of them also at the second one.
One patient might have had a recurrent infection be-
tween the episodes without attending the hospital clinic.
The four glycoprotein genes were sequenced in all
HSV-2 isolates. Sequencing spanned the entire open
reading frames and a variable number of nucleotides in
the 5′- and 3′- untranscribed regions of each gene.
When analysing the results from each patient separately,
comparing sequences from primary to recurrent infec-
tion, no difference was detected in any patient, as indi-
cated in Figure 1. One might not expect a substantial
variation due to mutation, since proof reading during
synthesis of HSV-DNA has been reported to be efficient
and the rate of nucleotide substitution estimated to be
3 × 10-8 per site per year [34]. Similar genetic stability of
HSV-2 has been observed under other conditions. Ter-
hune et al. [35] studied isolates of HSV-2 propagated in
cell culture and did not observe sequence variation in
any of the genes encoding gB, gC and gD, respectively.
Figure 1 also shows the genetic relationship between the
viruses isolated from the 5 patients. All 5 isolates are
clearly different.
There was no indication of recombination, but we cannot
exclude the possibility that it might have occurred, asFigure 1 Genetic relationship between the viruses included in the stu
sequences of the genes encoding gB, gG, gI and gE.discussed below. For recombination to occur, at least two
different viruses have to infect the same host. Such infec-
tion could be in previously uninfected sensory neurons
since only a small portion of neurons harbour virus DNA
in the latent state. For HSV-1 this has been shown to be be-
tween 2% and 11% [36]. However, two different viruses
could also infect a single neuron, as shown for HSV-1 and
VZV [37]. Since reactivation of HSV-2 is a commonly oc-
curring event, several of them being asymptomatic [18-20],
the patients could repeatedly be exposed to HSV-2 during
the study, through their partners. The partners were not in-
cluded in the study. Absence of detectable recombination
could suggest that, in a given couple, the same type of virus
was present at all times. Alternatively, the dose of a
second virus could have been too low to establish a
new infection [38].
All genes in the present work encode glycoproteins
present in the viral envelope. Among their important
roles are involvement of gB in binding virus to the cell
membrane, and gE and gI acting in axonal transport of
capsids and/or virions [21]. Since gG of HSV-2 is larger
than that of HSV-1, it has been used as a tool for sero-
diagnosis of HSV-2 infection [28]. The total number of
nucleotides in the open reading frames of these genes is
approximately 5% of the total HSV-2 genome. Thus, the
possibility should be left open that sequence variation,
including recombination, might have occurred in the
period from primary to recurrent infection in parts of
the viral genome outside the analysed portions.
Conclusions
Although infections of cell cultures and animal models
are very useful for studies of herpes simplex virus (anddy. The tree is based upon the open reading frame nucleotide
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haves in the natural host. We have studied lesional virus
isolates from humans with genital HSV-2 infection and
observed that several glycoprotein gene sequences are
stable from primary to recurrent infection. However,
isolates from the different patients were genetically
different.
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